Anti-CD3 monoclonal antibody

Drug Profile

Anti-CD3 monoclonal antibody

Alternative Names: Bispecific immunoadhesion antibody; Monovalent anti-CD3; Monovalent anti-CD3 monoclonal antibody

Latest Information Update: 13 Jun 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Cambridge; University of Oxford
  • Developer INSERM; Necker Hospital; Nextran; University of Cambridge; University of Chicago
  • Class Monoclonal antibodies
  • Mechanism of Action CD3 antigen inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer; Renal transplant rejection; Transplant rejection; Type 1 diabetes mellitus

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 17 Apr 2002 No development reported - Preclinical for Transplant rejection (unspecified route)
  • 17 Apr 2002 No development reported - Preclinical for Type-1 diabetes mellitus in France (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top